,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'breast', 'destiny-breast04']
t-dxd as new soc therapy option for her-2 low metastatic breast cancer (mbc) failing prior therapy based on destiny-breast04 ph3rct received with huge audience applaud! #asco22 
Regional Cancer Research Director @CleveClinicFl #Scientist #Immune #Oncology #Epigenetics #Cancer #Sensitisation #TIME #StayPositive. Tweets are mine.